India's GLP-1 Shakeout Is Coming

Morgan Stanley just called India the “blueprint” for global GLP-1 generics. The data backs it up. 26 generics, 13 companies, 6x volume growth in four months post-patent-expiry.But their supply chain call doesn’t hold. They say there’s “no API bottleneck” coming. We’re already living the counter-example of Dr. Reddy’s semaglutide API halt this year cascaded straight through to white-label partners Torrent and USV. Aggregate Chinese capacity doesn’t protect you from a single-supplier quality event.In this episode, I discuss the Morgan Stanley GLP-1 podcast:* Why the $1B-by-2030 India number is a category call, not a company call - 26 generics won’t all survive the shakeout * Why supplier concentration risk is the real story the “no bottleneck” framing misses* Why the strategic fork isn’t semaglutide pricing, it is where you sit on tirzepatide and non-peptide oral GLP-1s * Why peptide vs. non-peptide oral manufacturing is the most important line in the whole transcriptListen in! “My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com